Should Investors Worry About Moderna Insiders' Increased Stock Sales?
Moderna (NASDAQ: MRNA) announced positive interim results from a phase 1 study of its COVID-19 vaccine candidate mRNA-1273 on May 18, 2020. Its shares immediately skyrocketed. And several top executives promptly sold some of their Moderna shares.
While the insider selling raised some eyebrows, there was nothing amiss. Each of the Moderna executives who sold shares had done so using a Rule 10b5-1 trading plan. These plans allow company insiders to establish trading plans to buy or sell preset numbers of shares at preset times.
But now another controversy has arisen regarding Moderna's management selling increased numbers of shares. Is there anything for investors to worry about this time?
Source Fool.com
